Due to the progressive nature of type 2 diabetes, its complexity and drug treatment perpetuity, there is currently a search for surgical procedures that can promote euglycemia also in non-obese patients. Diabetic patients glycemic control can be achieved by increasing the blood concentration of GLP-1, a hormone produced by L cells that are more densely concentrated in the terminal ileum. Early and extended improvement of diabetes in patients submitted to bariatric surgeries awakened the necessity of investigating the isolated ileal interposition as surgical alternative for the treatment of diabetes. The interposition of this ileal segment to a more anterior region (proximal jejunum) can promote a greater stimulation of the L cells by poorly digested food, increasing the production of GLP-1 and reflecting on glycemic control. However, in order to consolidate the ileal interposition as a surgical treatment of diabetes it is necessary that the interposed ileum keep the same differentiation rate into L cells for a long period to justify the intervention.
INTRODUCTION
Diabetes is one of the most common chronic diseases and a growing global epidemic (Danaei et al., 2011) .
1 Type 2 diabetes (T2D) is a serious metabolic disease characterised by high glucose levels. Complications from T2D usually result in poor quality of life, disability, and early death. 2 Despite efforts to control glycaemia in diabetes patients, no therapeutic approach has significantly impacted the progression of this disease (Tahrani et al., 2010) . 3 There is, however, a simple and reversible surgical procedure that might become a valid therapeutic alternative in non-obese patients. This procedure, isolated ileal interposition (III), results in a dramatic increase in the incretin glucagon-like peptide 1 (GLP-1).
Epidemiology and aetiopathogenesis of diabetes
In 2000, diabetes caused the death of about three million people. 4 In 2010, the number of affected individuals was approximately 285 million, and this number is projected to increase 54% by 2030. A much greater increase in the number of adults with diabetes is projected in underdeveloped countries than in developed countries: the number of affected individuals is projected to increase approximately 70% in underdeveloped countries and 20% in developed countries. 1 T2D, also known as non-insulin-dependent diabetes, is responsible for 90% to 95% of diabetes cases.
5
T2D is a progressive heterogeneous disease that mainly involves peripheral insulin resistance and gradual dysfunction of pancreatic beta cells. 2, 6 It develops when pancreatic islets can no longer maintain insulinaemia at levels sufficient to overcome peripheral tissue resistance. Throughout the course of the disease, diabetes passes through intermediate stages. Initially, diabetes is treated only with modifications in lifestyle and specific diet. Later in the disease, patients are treated with drugs that promote insulin secretion. As insulin deficiency unavoidably increases, however, the combination of therapeutic oral agents often fails to control hyperglycaemia efficiently, and the use of insulin is eventually required. [6] [7] [8] [9] In the long run, patients with T2D have an increased risk of complications that are a substantial cause of morbidity and mortality, including macrovascular disease, nephropathy, retinopathy, and neuropathy. 10 Further complications of diabetes include ischemia of the limbs resulting in amputation, dental problems, and pregnancy disorders. 5 The risk of developing diabetes-associated complications is related to the duration of diabetes and the level of glycaemic control.
Although 90% of T2D cases can be attributed to excessive weight, 12 its incidence is growing among individuals with body mass index (BMI) in the normal and overweight ranges.
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Treatment of diabetes T2D is a multifaceted condition requiring an integrated and individualised approach to each patient's care that can prove quite challenging (Freeman, 2010) . 15 Treatment must initially be based on substantial lifestyle changes, including diet adjustment and regular physical activity. In most patients, these behavioural measures eventually do not suffice to keep glycaemia within appropriate levels, and oral antidiabetic agents are added. 17 Currently, there are several drug classes with different mechanisms of action that might be used singly or in various therapeutic combinations. 16 Many patients eventually require combinations of two or more oral drugs. [17] [18] [19] Despite these treatments, glycaemia increases over time as the disease progresses, requiring the use of insulin in combination with oral agents and eventual full insulinisation. Although these interventions might decrease peripheral blood glycaemia, none of these actions is effective in stopping disease progression. 9 Intensification of insulin therapy is the most appropriate intervention used to attempt to achieve normoglycaemia and reduce complications through early, strict, persistent, and effective control of glycaemia. 16, 20, 21 Thus, insulin is currently the only effective conservative therapeutic option for achieving metabolic control. 6, 7, 22 However, the use of external insulin is not easy to manage. Attaining optimal glycaemic levels, i.e., glycaemia levels as close as possible to those of a non-diabetic individual 23 in order to prevent complications, still poses a major challenge in clinical practice. 2, 21 Due to the limitations of most of the available therapeutic measures, only a small fraction of the diabetic population meets therapeutic goals. 23 These limitations include poor compliance with diets, resistance to physical exercise programmes, limited efficacy and significant side effects of current therapeutic agents, delays in insulin therapy onset, and patient aversion to the multiple parenteral injection regimes required for the administration of insulin. [21] [22] [23] [24] Successful insulin therapy requires accurate information, motivation, high socioeconomic and cultural levels, high adherence and learning ability, availability of resources, and participation of and support by a multiprofessional team.
Some antidiabetic drugs accelerate beta cell apoptosis, 2 whereas others reduce bone mineral density and promote weight gain due to volume expansion and oedema, potentially causing or exacerbating heart failure and triggering ischemic cardiac events. 17, 18 Some insulin analogues are associated with a more physiological pattern of recovery; these drugs are more flexible to use and convenient to prescribe, and they allow greater freedom in diet while still providing improved quality of life. 6, 7, 25 Formulations eliminating the need for subcutaneous injections might correct some limitations of typical insulin therapy, thus improving glycaemic control and increasing patient quality of life. 21 Some formulations that allow non-invasive administration of insulin are in the testing phase, including the inhalable insulin powders Exubera (Pfizer), Technosphere (MannKind), Aerdose (Aerogen), BAI (Kos), Alveair (Coremed),
and Bio-Air (BioSante). Therapy selection must take into account tolerability, non-glycaemic effects of antidiabetic agents, effects on associated comorbidities, and cost (Stolar et al., 2008) . 17 The limitations of conventional treatments that fail to preserve pancreatic beta cell function over time have resulted in a critical need to find new means to attain appropriate glycaemic control and avoid or delay the need for additional measures . 2 Thus, antidiabetic treatments seeking to preserve beta cell function and integrity and halt T2D progression are clearly needed. 8 More effective measures based on the disease aetiopathogenesis are necessary; these measures must control both fasting and postprandial glycaemia.
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A new approach to T2D treatment involves the use of therapies based on incretins such as dipeptydil peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists, which are GLP-1
analogues and bind to GLP-1 receptors on pancreatic beta cells to inactivate them. 2, 3 Both groups of drugs have proven safe and effective in reducing glycaemia and have yielded favourable effects regarding weight, lipid profile, and blood pressure. 9, 17, [26] [27] [28] Both are associated with insulin release and glucose-dependant glucagon suppression with consequent low hypoglycaemia risk. Experimental studies showed that these therapies prolong the survival, delay the dysfunction, and promote the regeneration of pancreatic beta cells and thus theoretically hold the potential to halt T2D progression. 3, 9, 28 Although these studies have demonstrated the therapeutic promise of DPP-4 and GLP-1 analogues, the high cost of these new agents and the lack of studies on their long-term safety must be considered. Nausea, headache, acute pancreatitis, upper airway infection, depression, severe hypoglycaemia, and skin allergic reactions have been reported with the use of these drugs. Some individuals also exhibit moderate reduction of glycated haemoglobin levels when compared to patients treated with insulin and older agents. Moreover, the development of carcinomas has been associated with the use of these agents in guinea pigs;
however, this finding has not been confirmed in humans. 18, 19, 28 In addition to the wide variety of pharmacological options for multidisciplinary treatment aimed at weight loss and glycaemic control, bariatric and metabolic surgical techniques can be included among the therapeutic approaches to T2D and insulin resistance.
These surgical interventions have been shown to provide long-term control of T2D.
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Surgical interventions
Bariatric surgery can improve and eventually completely reverse obesity-associated comorbidities in 70% to 100% of patients, 31 thus increasing their life expectancy, 32 partially reversing hypothalamic dysfunction, and increasing the anti-inflammatory activity of the cerebrospinal fluid.
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Improved glycaemic control is observed months after adjustable gastric band surgery, and improvement is faster and more complete with ROUX-en-Y bypass. Both strategies can improve or even cure T2D, potentially through different mechanisms (Meijer et al., 2011) . 34 Vertical gastrectomy with or without contention ring and Roux-en-Y gastrojejunal bypassthought to be the gold standard surgical intervention in the treatment of morbid obesity -are known to achieve the goals of weight loss and control of comorbidities and to maintain these goals over time. 35 This control of comorbidities is usually attributed to body mass reduction;
however, a potentially glycaemia-controlling endocrine effect has been observed even before any significant weight loss. 36 After gastrojejunal bypass, levels of substances directly secreted by the bowel such as GLP-1 were found to be elevated in the peripheral blood; these substances can stimulate insulin production by pancreatic beta cells, facilitate insulin-mediated glucose transport into cells, and induce a feeling of satiety. 37 Roux-en-Y gastrojejunal bypass favours the stimulation of GLP-1-producing cells by foods arriving at the distal portions of the small intestine incompletely digested, as food transit is diverted to the proximal jejunum. 38 Jejunal bypass and other highly effective bariatric and metabolic surgical interventions deliver nutrient-rich chyme to the distal bowel earlier than normal. Its arrival directly to the ileum activates a negative feedback mechanism known as the "ileal brake", 39 which involves neuronal and endocrine mechanisms that influence stomach voiding, intestinal motility, and satiety.
As early as 1998, it was already thought that T2D might be an anterior bowel disease. 41 Currently, several clinical, physiological, biological, anthropological, epidemiological, anatomical, and evolutionary lines of evidences together with surgical results have confirmed that the proximal small intestine -whose size was appropriate for our ancestral environmentmight have become too large due to the modern industrialised diet. Consumers of a rich and modified modern diet developed a much larger anterior intestine (jejunum) than desired. A shorter jejunum prevent ingested food from being fully absorbed in the proximal portion of the intestine, allowing it to arrive at the distal intestine (ileum) almost in natura in order to stimulate L-type endocrine cells to produce substances such as GLP-1 that promote insulin production by the endocrine pancreas, facilitate glucidic metabolism in peripheral tissues, and induce satiety through selective hypothalamic inhibition. 42 The genesis of disruptions in glucose metabolism involves a multifaceted range of intimately intertwined factors. Of these factors, hormones are the most significant; of particular interest is GLP-1, which is produced by enteroendocrine L-cells of the small intestine, which are more densely concentrated at the terminal ileum. 32 GLP-1 is produced by tissuespecific post-translational processing of its precursors, namely, the peptide proglucagon, by pro-hormone convertase enzymes. 43 Post-translational modifications of the glucagon gene give rise to five different products in the bowel: glycentin, oxyntomodulin (OXM), intervening peptide-1 (IP-1), GLP-1, and GLP-2. 44 Proglucagon is processed in bowel L-cells by PC1/3 prohormone convertase. 43 GLP-1 secretion occurs in response to stimuli generated by nutrients with an incretin effect. 45 Incretins are hormones secreted into the blood circulation by the gastrointestinal tract in response to intake of certain nutrients. This results in increased insulin production and consequent glucose uptake. GLP-1 has well-defined functions, such as stimulation of glucose-dependent insulin secretion, upregulation of insulin gene transcription, induction of Langerhans islet beta cell neogenesis and proliferation, inhibition of beta cell apoptosis, increased phenotypic differentiation of beta cells, stimulation of somatostatin production, and reduction of glucagon production. 46, 47 Advances in neurogastroenterology have provided a better understanding of gastrointestinal physiology. Therefore, bariatric surgery intervention modalities evolved into the current mixed procedures that take into account neurohormonal and metabolic factors in addition to restriction and dysabsorption features. Thus, the term baroendocrine surgery is increasingly used, especially in the treatment of T2D. 38, 40 Currently, mixed (restrictive and dysabsorptive) bariatric surgery is the most efficacious treatment in patients with morbid obesity, resulting in significant improvement of associated comorbidities (Melissas, 2008) . 49 In studies of these interventions, enhanced GLP-1 release and improved glycaemic control have been observed even before significant weight loss, demonstrating that the control of diabetes might be related to hormonal effects secondary to the surgical technique performed.
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Isolated ileal interposition
In the early 1980s, enhanced GLP-1 release had already been shown to suffice for body weight control in obese rats treated with the interposition of a 5-or 10-cm terminal ileum fragment. 51 The effects of this surgery are illustrated in Figure 1 . (5) GLP-1 is an incretin and will also mediate insulin secretion and endocrine pancreas protection. 52 Another study in rats showed hypertrophy of transposed ileum together with increased serum GLP-1 levels. 53 In humans, GLP-1 increased after jejunoileal and biliopancreatic bypass in morbidly obese individuals. 54 Another study published in 1998
showed that patients exhibited high levels of GLP-1 even 20 years after jejunoileal bypass.
Together with a study published in 1999, these findings suggested that ileal interposition might be used as a treatment for T2D. 56 Fast and permanent improvements in glucose control were observed in patients immediately after bariatric surgery, and surgery eliminated the need for glycaemia-controlling drugs in most cases. 57, 58 The beneficial effects of bariatric surgery on glycaemic control also depend on the duration of disease 59 and the type of surgical intervention; interventions based solely on stomach restriction, such as adjustable gastric bands, proved to be less effective in improving T2D than procedures involving substantial amounts of intestinal bypass 55, 60, 61 or significant increases in digestive transit speed, such as vertical gastrectomy. 62, 63 Vertical gastrectomy is aimed mainly at achieving weight loss. It is a restrictive procedure due to the significant reduction in stomach reservoir capacity; moreover, it is considered a metabolic procedure, as it results in reduced circulating levels of the orexigenic hormone ghrelin, which is produced at the fundus and greater curvature of the stomach.
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The good long-term postoperative 64 glycaemic control achieved by vertical gastrectomy 63 might be due to the arrival of incompletely digested food at the distal ileum as a result of increased voiding speed after surgery, which in turn results in increased GLP-1 secretion by Lcells. 66 Ileal interposition has frequently been performed in obese and non-obese humans;
however, it is never performed in isolation. Promising results were recently obtained in humans using techniques combining vertical gastrectomy with the interposition of a segment of distal ileum in the trajectory of the proximal jejunum. [67] [68] [69] [70] [71] [72] This procedure can induce early satiety along with benefits to glucidic metabolism and cause short-and long-term weight loss.
In non-obese diabetic patients, vertical gastrectomy combined with ileal interposition effectively controlled T2D. [67] [68] [69] [70] [71] Analysis of the effects of vertical gastrectomy combined with ileal interposition on humans 6 and 18 months after the procedure demonstrated T2D remission in 80% of patients, who were freed from treatment with hypoglycaemic agents or diet. The remaining 20% of patients showed significant improvement despite the need to continue oral treatment (Tinoco, 2011 ).
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Despite these findings, however, there is a conceptual problem in proposing to perform vertical gastrectomy in non-obese diabetic patients: the metabolic benefits reported in the literature were probably due almost exclusively to ileal interposition rather than to the partial gastric restriction procedure (vertical gastrectomy).
The early postoperative improvement in glucose metabolism observed in obese and diabetic patients subjected to vertical gastrectomy alone 63 is most likely due to the increase in intestinal transit speed induced by intervention, 66 which favours quicker arrival of undigested food to the terminal ileum, where it stimulates L-cells to produce endogenous GLP-1. We conclude that in these non-obese patients with glucidic dysmetabolism, vertical gastrectomy improves glucose metabolism, but this effect is only due to the acceleration of gastrointestinal transit, which causes incompletely digested food to arrive at the terminal ileum, where it triggers GLP-1 production by L-cells. Other consequences of vertical gastrectomy, such as the restriction caused by making the gastric reservoir a small-calibre tube, and the anorexigenic effect caused by reducing levels of the orexigenic hormone ghrelin, 63 arise from the removal of the fundus and greater curvature of the stomach, where X/A-type neuroendocrine cells are more concentrated. However, vertical gastrectomy is a major surgical procedure that is not without significant complications, such as torpid evolution of fistulas and reflux esophagitis.
There is no reason to apply this procedure to non-obese diabetic patients, in whom isolated ileal interposition may be highly effective. Ileal interposition in rats involves placing a 10-to 20-cm segment of distal ileum with its nerves and vessels intact into the proximal jejunum, 73 resulting in significant hyperplasia, hypertrophy, and even full "jejunisation" of the transposed ileum. [74] [75] [76] [77] [78] Isolated ileal transposition proved efficacious in correcting dysmetabolism in several studies of experimental animals; 51, 79, 80 however, in the context of bariatric and metabolic surgery, this surgical modality involving only ileal interposition has not been assessed in humans.
Increased synthesis and release of GLP-1 can be attributed to increased stimulation of L-cells located in the interposed ileum segment in response to the presence of a greater amount of partially digested food, resulting in direct effects on glucidic metabolism (Patriti et al., 2007) . 81 Serum levels of GLP-1 increase in response to alimentary stimulation, resulting in a satiating effect on the central nervous system, 82 reduced fat absorption by the gastrointestinal tract, 83 and reduced gastric 84 and intestinal motility. 85 The most remarkable effects of GLP-1 are reduced peripheral insulin resistance, decreased apoptosis of pancreatic beta cells, increased differentiation of primitive pancreatic canaliculus cells into adult beta cells, and increased proliferation of beta cells. 86, 87 GLP-1 is the incretin hormone most associated with the antidiabetic effects of bariatric surgery. Stimulation of ileal L-cells to cleave proglucagon and release GLP-1 seems to be the most effective means of inducing the incretin effect in diabetic patients subjected to bariatric surgery. Several techniques might be applied to achieve this effect. All of these techniques are derived from the hindgut theory, which states that contact of partially digested food with the ileum corrects the deleterious effects of "empty ileum syndrome" caused by the lack of L-cell stimulation. 61, 81, 88 The results of the simple interposition of an ileum segment into the proximal segments of the small intestine are the strongest arguments supporting this hypothesis. A study of interposition in experimental animals subjected to a model of diet-induced obesity showed a significant increase in GLP-1 levels (Strader, 2006) . 52 Similarly, interposition of a 50-cm ileum segment distal to Treitz's angle in combination with vertical gastrectomy resulted in improved diabetes symptoms in a clinical trial. 89 In addition to the "ileal brake" (a reaction that decreases proximal gastrointestinal transit motility and enterohormone 90, 91 production following ileal interposition surgery), ileal interposition also improved glucose tolerance in experimental, euglycaemic rats.
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These findings suggest that isolated ileal interposition might be a valid alternative for the treatment of diabetes. Due to the intestines' great capacity for adaptation, further research is necessary to justify ileal interposition as a surgical treatment for diabetes.
Specifically, studies addressing the ability of interposed ileum L-cells to continue to differentiate with a density similar to intact ileum; to fulfil their functions, including GLP-1 production, over time; and to contribute to the metabolic control of glucose levels will be necessary.
Cell differentiation and intestinal adaptation
Cells of the small intestine constantly proliferate and differentiate, and they are able to adapt after injury, inflammation, or resection. 93 The intestine is known to be able to adapt morphologically and functionally in response to internal and external stimuli. Intestinal adaptation, also known as enteroplasticity, is a complex and multifaceted process that serves as a paradigm for gene-environment interactions. Adaptation can occur after the loss of a small portion of intestine, in diabetes, with age, or due to malnutrition. [94] [95] [96] [97] Increased nutrient absorption after intestinal resection compensates for absorption surface loss and minimises malabsorption 98 by increasing crypt depth, villus length, enterocyte proliferation, and absorption of electrolytes, glucose, and amino acids.
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Several studies aiming to elucidate the basis of the adaptation response showed that digestive and absorptive properties are increased coordinately with the expression of enteroendocrine genes. [101] [102] [103] Peptides derived from proglucagon, an adaptation response marker, act as humoural mediators; ileal levels of proglucagon increase after small intestine resection. Proglucagon messenger RNA (mRNA) levels increase specifically in the ileum. This increase is immediate and persists for up to three weeks after resection. 104 Multiple complex factors, including humoural factors such as the growth factors insulin-like growth factor 1 (IGF-1), peptide YY (PYY), epidermal growth factor (EGF), and GLP-2, biliopancreatic secretions, and nutritional factors (glutamine, arginine, fatty acids, and triglycerides), also influence the mechanism of intestinal adaptation. 93 Dietary components supply continual signals inducing the expression of genes that influence intestinal adaptation. 105 The amount and type of dietary fat consumed can influence intestinal function. 106 Carbohydrates can induce the intestinal adaptation response by increasing hexose transporter levels in order to increase sugar absorption. 107 Alterations in the amount of ingested protein induce adaptations in the transport of non-essential amino acids. 108 Biliary acids solubilise fat and participate in complex hormone metabolism by activating nuclear receptors, which control the transcription of genes also involved in glucose 
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The proglucagon gene encodes two hormones with important functions and opposite effects on glucose homeostasis: glucagon, which is expressed in pancreatic islets, and GLP-1, which is expressed in the bowels. The tissue-specific regulation of proglucagon expression remains poorly understood. In endocrine cell lines, the glucagon promoter is stimulated by beta-catenin, which is the main effector of the Wnt signalling pathway. GLP-1 synthesis and mRNA expression are activated by the inhibition of glycogen synthase kinase 3β, which is the main negative modulator of the Wnt pathway. In addition to demonstrating a specific mechanism for the regulation of proglucagon expression in intestinal endocrine cells, this study suggests that tissue-specific expression of the factors TF and TF-4 plays a role in the diverse Wnt signalling pathways. 114 Several hormones, such as glucocorticoids and the growth hormones IGF-1, EGF, keratinocyte growth factor (KGF), leptin, ghrelin, and GLP-2, can modify intestinal shape and function. It is clear that genes regulating cell cycle, proliferation, differentiation, and apoptosis are important components of the adaptation process (Drozdowski et al., 2009 ). 97 Several studies in humans and laboratory animals showed that after massive resection of the proximal small intestine, the remaining ileum exhibits morphological and functional adaptation in an attempt to preserve nutritional health by increasing ileal absorption of dietary nutrients. The authors of these studies concluded that the ileal adaptation mechanisms for peptide absorption are mediated by cell proliferation, i.e., villus hyperplasia and intestinal dilatation, which serves to increase the absorption surface. regulating elements that contribute to the specific genetic profile of each cell type is increasing the understanding of the different networks controlling the spatial and temporal activation of enteroendocrine differentiation programmes. 122 EECs secrete several regulatory molecules that control physiological and homeostatic functions, mainly postprandial secretion and motility, and act as sensors of lumen contents. 123 Although EECs secrete transcriptional regulators, they differentiate from pluripotent stem cells located in crypts. Their origin is therefore endodermal as with all epithelial mucosa cell types. [124] [125] [126] The Wnt signalling pathway plays an important role in the proliferative activity of the normal intestinal crypt. 127 The Lgr5/GPR49 gene is only expressed in the stem cell compartment located at the crypt bottom, demonstrating that all epithelial lines derive from Ldr5-expressing intestinal stem cells. 125 EEC spatial orientation along the crypt-villus axis is known to be closely associated with differentiation. Although most EECs differentiate and migrate towards the villus top, a recent study showed that a small EEC subpopulation that migrates towards or remains at the crypt bottom expresses stem cell markers and post-mitotic endocrine markers. 128 A fourth type of secretory cell, referred to as tuft cells, Ngn3 is a bHLH transcription factor that is activated on embryonic day 11.5. 144 Its expression persists in the adult bowels and the glandular portion of the stomach. 136 Genetic analyses of NeuroD provided the first link between Notch signalling and EEC differentiation. 139 In contrast to Ngn3, NeuroD expression is restricted to a subgroup of secretin-producing EECs. Transcription factors other than bHLH factors also seem to play important roles in EEC differentiation. In addition to the early EEC differentiation observed in Hes1-deficient animals, Pax4, Pax6, Nkx2.2, and Isl-1 genes were activated in the intestine. 132 Instead of controlling EEC global differentiation like bHLH genes, these factors seem to play important roles in the fine control of specification decisions among enteroendocrine populations. 119 LIM homeodomain genes encode a family of transcription regulating proteins involved in the control of several aspects of embryonic development and are responsible for some human diseases. Islet-1 (Isl-1)
is expressed in gastrointestinal epithelium on approximately embryonic day 10, and in adults, its expression is restricted to EEC subgroups. Expression analysis suggests that Isl-1 might play an important role in the final differentiation and/or maintenance of mature enteroendocrine subtypes in the gastrointestinal epithelium.
In the adult intestine, the zinc-finger transcription factor Gfi-1 is mainly found in crypts. Its expression is restricted to neuroendocrine lineages, and it acts downstream of Math1 in the differentiation process. Gfi-1 is a transcriptional repressor that acts in secretory lineage differentiation, specifically in the selection between enteroendocrine progenitors and other lineages (goblet and Paneth). Expression of Gfi-1 was detected in adult small intestine and colon crypts and villi. Gfi-1 co-localises with Math1, Ngn2, serotonin, and chromogranin A, but not with goblet and Paneth cells markers. These data suggest a model for intestinal epithelial differentiation in which Gfi-1 expression must be abolished for normal differentiation of goblet and Paneth cell progenitors ( Figure 5 ). Alternatively, Gfi-1 might only be expressed in Math1/Ngn3-positive enteroendocrine precursors, whose production increases in the absence of Gfi-1, and serve to inhibit the production of goblet and Paneth cells from adjacent progenitors. 140 Figure 5. Model of intestinal epithelial cell differentiation. Stem cells give rise to highly proliferative multipotent progenitors that use Notch signalling to select Hes1-or Math1-expressing cells. Hes1-expressing cells differentiate into absorptive enterocytes, and Math1-expressing cells are the secretory lineage progenitors. Next, these progenitors co-express Gfi-1, which selects between goblet and Paneth cell progenitors (green) and enteroendocrine precursors (brown). Enteroendocrine precursors express Ngn3 and Gfi-1, which continues to be expressed in a subgroup of mature EECs. binds to G1 and G3 elements in the proglucagon promoter to activate its transcription. 158, 159 Pax6 might also bind to the promoter and induce production of PC 1/3 pro-hormone convertase, an enzyme essential for the conversion of proinsulin into insulin 160 and of proglucagon into GLP-1. 43 Proglucagon processing is accomplished by PC1 in L-cells and by PC2
in pancreatic alpha cells to produce glucagon. Published data suggest that these tissue-specific processing mechanisms are due to differential expression of PC1 and PC2. This study showed that GATA4 is crucial for jejunum function and plays an essential role in the determination of jejunal versus ileal identity. It has been shown that GATA4 or GATA6 is necessary for secretory progenitors to commit to a neuroendocrine lineage. [167] [168] [169] Immunohistochemical analysis of mouse small intestine revealed that GATA4 is only expressed in villus enterocytes. GATA5 was not detected in enterocytes, but it was detected in other lineages. High levels of GATA6 were only detected in the neuroendocrine lineage. Together, these results suggest that GATA transcription factors may play different roles in the differentiation and/or allocation and maintenance of small intestine lineages. Examination of the patterns of gene expression in animals during the adaptation process has revealed that some metabolism-related genes are increased at least two-fold after resection.
Changes in the expression of genes encoding ion channels, transport proteins, transcriptions factors, DNA-binding proteins, receptors, and cytoskeleton proteins were also observed. 173, 174 One study using DD-PCR showed that adaptation after resection results from the up-regulation of genes not previously related to the adaptation response. Genes that exhibited differential regulation after resection were divided into three categories: amino acid transport, protein transport, and signal transduction molecules. This same study suggested that analyses using reverse transcriptase polymerase chain reaction (RT-PCR) can more precisely define the magnitude of the adaptation response. 93 To study adaptation after 50% resection of the mouse intestine, cDNA microarrays were used to characterise the expression of individual genes and global gene expression patterns in the remaining ileum. The analysis of these microarrays revealed changes in the expression of several genes, including those involved in cell cycle regulation, apoptosis, DNA synthesis, and transcriptional regulation. Expression patterns were consistent with the increase in cell proliferation and apoptosis observed during intestinal adaptation; however, verification by RT-PCR and Northern blot are still necessary. 173 Another study examined gene regulation after resection in mice using cDNA microarrays and showed that 27 genes were altered after resection; these genes included sprr2, which increased almost five-fold and had not previously been linked to intestinal adaptation. 
AIMS Overall
To assess the effects of isolated ileal interposition on intestinal stem cells of rats with dietinduced glucidic dysmetabolism.
Specific
To investigate changes in the relative expression of genes involved in intestinal stem cell differentiation into enteroendocrine cells after isolated ileal interposition.
To analyse changes in the number and function of L-cells after isolated ileal interposition.
METHODS
Research Ethics Committee
This research project will be presented to the Experimental Research Ethics Committee of the Federal University of São Paulo -São Paulo School of Medicine (UNIFESP/EPM).
Experimental procedures
Experimental procedures will be performed according to guidelines in the manual All animals will be provided the same diet and will be subjected to surgery when they become dysmetabolic. Blood samples will be collected from all animals on the days of surgery and euthanasia for biochemical analysis. After euthanasia, samples will be collected from the interposed and remaining ileum of the interposition group and from the jejunum and ileum of the control group. These samples will be analysed using molecular biology and immunofluorescence techniques to compare changes in the small intestine segment under study relative to the characteristic endocrine pattern of the ileum.
Sample
Twenty male Wistar -2BAW heterogeneous male rats (Rattus norvegicus albinus) aged 12 weeks and weighing between 250 and 280 g will be used. The animals will be supplied by the Laboratory of Animal Experimentation at the Institute of Pharmacology and Molecular
Biology of the Federal University of São Paulo -São Paulo School of Medicine (UNIFESP/EPM), where they will be housed throughout the study.
Animals will be housed in individual cages and kept for 32 weeks at a controlled ambient temperature of 23 2 C, relative humidity of 55 15%, and automatic 12-hour lightdark cycle (06:00 / 18:00) (Timer-Kienzle).
For surgical procedures, animals will be randomly distributed into two groups according to the flowchart defined below:
-Interposition Group (IG) -10 animals subjected to ileal interposition -Control Group (CG) -10 animals not subjected to any surgical intervention Surgical interventions will be performed at post-natal week 28 (W28) or as soon as glucidic dysmetabolism is established. All animals will be monitored until euthanised in the 16 th post-operative week, which will be equivalent to post-natal week 44 (W44). 
Diet
Throughout the experiment, all animals will be provided a lipid-rich pelletised hypercaloric diet (HD) ad libitum in alternating cycles of four feed types (1, 2, 3, and 4) to stimulate intake. The experimental feed will be alternated every 24 hours, and non-ingested amounts will be measured. Consumption of these diets will promote obesity in animals, which will exhibit characteristics commonly associated with human obesity, such as insulin resistance, hyperglycaemia, hyperinsulinaemia, dyslipidaemia, and liver steatosis. All groups will have free access to water.
Experimental feeds 1, 2, 3, and 4 will be industrially prepared by Rhoster®, Araçoiaba The macronutrient composition of the standard and hypercaloric-hyperlipidic experimental feeds prepared and analysed in the laboratory by Rhoster®, Araçoiaba da Serra -SP is described in Table 1 . 
Weight and ration intake curve
As soon as the clear period begins, the animals will be weighed twice per week on preestablished days using appropriate high-precision scales (Filizola BP-6), and each animal's weight in grams will be recorded. Feed intake will be recorded three times per week on preestablished days; in each cage, the difference between offered and consumed feed will be calculated, and estimated daily feed intake will be expressed in grams. Weight and feed intake curves will be calculated for both groups throughout the study.
Blood collection and laboratory tests
Six hours before blood collection and surgical procedures, animals in all groups will be subjected to fasting with access to water ad libitum. Blood will be collected for laboratory tests on the week 12 (W12), two weeks before surgery (W26), eight weeks before surgery (W36) and on the day of euthanasia during the 16 th post-operative week (W44), after weighing and under anaesthesia.
In total, 0.5 mL of blood will be collected from each animal in tubes containing 5 μl of DPP-IV inhibitor (an enzyme that degrades GLP-1) by caudal vein puncture. The blood samples will then be centrifuged, and serum will be stored at -20°C until analysis of serum levels of active glucagon-like peptide-1 (GLP-1), glucagon, insulin, and other diabetes-related analytes.
For this purpose, we will use the Milliplex® Magnetic-Metabolism (Rat Metabolic Disease, Genese, SP) simultaneous quantification method.
Ten minutes after blood collection, serum glucose will be measured with reagent strips on a glucometer (Kit Accu-Chek Advantage®). Next, the animals will be subjected to an insulin tolerance test (ITT). Regular insulin will be injected in the penian vein at a concentration of 1 U/kg body weight. One drop of blood will be collected from the tail using a lancet 4, 8, 12, and 16 minutes after insulin injection for the detection of glycaemia. The results will be recorded for later analysis.
Serum glucose will also be measured weekly on pre-established days throughout the study (W14 to W44) using reagent strips and a glucometer (Kit Accu-Chek Advantage®).
Anaesthesia, weighing, and antibiotic prophylaxis
Before the onset of anaesthesia, all animals will be weighed on high-precision scales (Filizola BP-6), and their weights will be recorded in grams. In both groups (IG and CG), general anaesthesia will be induced with halothane to collect tail blood. Dissociative anaesthesia will then be induced by simultaneously injecting the animals intramuscularly with Zoletil 50®
(tiletamine+zolazepam) at a dose of 20 mg/kg and Fentanil® at a dose of 0.025 mg/kg to perform the insulin tolerance test and surgical intervention.
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Each animal will be maintained on spontaneous ventilation during the procedure, and the anaesthetic plane will be checked periodically every 45 minutes by assessing the auricular and interdigital reflexes, which are abolished during anaesthesia. When these reflexes reappear, one-third of the initial anaesthetic dose will be administered. The total amount of anaesthetics used will be recorded at the end of the surgical intervention.
Antibiotic prophylaxis will be performed by intramuscular injection of cefoxitin at a dose of 50 mg/kg body weight soon after anaesthesia for surgery.
Surgical procedures
Rats in the IG group will be subjected to surgery upon developing diet-induced glucidic dysmetabolism, which should occur around 28 weeks of life (W28). All Halsted asepsis and antisepsis principles will be applied, and sterile microsurgical tools will be used.
The anaesthetised rats will be placed in horizontal dorsal decubitus on the surgical table with the legs and tail duly immobilised and secured with tape. Antisepsis of the abdominal area will be performed with chlorhexidine in an aqueous vehicle.
A sterilised fenestrated surgical drape will be placed on each animal's abdominal area, and a 5-cm long median longitudinal incision will be made in the wall with a disposable scalpel containing a number 15 blade.
The caecum will be identified in each IG animal and exposed together with the terminal ileum. Next, the small intestine will be sectioned perpendicularly in two areas 5 cm and 15 cm from the ileo-caecal transition, thereby producing a 10-cm segment of ileum. The ileum segment will be removed and wrapped in gauze moistened with 0.9% saline solution ( Figure 6A) . Next, the jejunum will be sectioned in an area 5 cm from the duodenum-jejunum transition ( Figure 6A ). The previously separated distal ileum segment will be interposed between the segments of sectioned jejunum in isoperistaltic position by means of enteroenteric anastomosis ( Figure 6B ). Next, anastomosis will be performed between the interposed ileum and the remaining ileum to re-establish the continuity of the digestive tube ( Figure 6C ). No surgical intervention will be performed on the CG animals.
All intestinal anastomoses will be termino-terminal and will be performed with a total of 6 separated points using 7-0 polypropylene sutures pre-mounted on cylindrical needles.
After completion of the final revision surgery, the animals will be hydrated by intraperitoneal injection of 1.0 mL crystalloid solution (0.9% physiological saline) per 300 g body weight at 36°C.
Abdominal wall synthesis will be performed by monoblock continual suture of parietal peritoneum, muscle layer, and aponeurosis using 4-0 polyglactin sutures pre-mounted on cylindrical needles. In the skin, continual suture with inverted stitches will be performed using 4-0 polyglactin sutures pre-mounted on cylindrical needles.
Postoperative assessment
Animals will be kept warm and observed until full recovery from anaesthesia, when they will be placed in individual cages and transported to the housing room in the same laboratory and under the same environmental conditions as before surgery.
Before recovery from anaesthesia, animals will be given analgesic by gavage (0.5 mL of 3 g/mL dipyrone in water). Water will be reintroduced ad libitum as soon as animals recover from anaesthesia. Dipyrone (1 g/100 mL in water) will be given during the first 72 postoperative hours. Access to food will be allowed 12 hours after surgery.
The animals will be assessed and monitored until the 16 th post-operative week (W44).
Euthanasia
On the 44 th post-natal week, the fasting, anaesthesia, weighing, and blood collection for laboratory tests will be repeated. Euthanasia will then be performed by decapitation according to the guidelines of the Brazilian Society of Laboratory Animals Science/Brazilian
College of Animal Experimentation -SCAL-COBEA.
Study parameters
-Body Weight: as soon as the clear cycle starts, each animal in each group (IG and CG) will be weighed on high-precision scales, and the weight will be recorded in grams (W1, W2, W3…, W32).
-Feed Intake: all animals will be given feed diurnally at a known amount sufficient for their daily needs; three times per week, non-ingested feed will be weighed on adequate scales, and daily feed intake will be calculated from the difference between supplied and remaining feed.
-Biochemical Tests: serum levels of active GLP-1 (GLP-1), glucose (GLI), insulin (INS), and glucagon (GLU) will be measured in all animals on week 12 (W12), two weeks before surgery (W26), eight weeks after surgery (W36) and euthanasia (W44).
-Insulin Resistance: on the days of surgery and euthanasia, insulin resistance (IR) will be calculated using the HOMA-IR indirect test (Homeostasis Model Assessment Insulin Resistance) from the product of serum insulin (mU/mL), glycaemia (mg/mL), and the constant 0.05551 divided by 22.5.
-Insulin Tolerance Test (ITT): will be performed in all animals on the day of study onset (W12), two weeks before surgery (S26), eight weeks after surgery (W36), and euthanasia (W44). The rate of glucose removal will be calculated using the formula In2/t1/2; t1/2 will be calculated for glucose from the minimum slope of the regression curve during the phase of linear decay of serum glucose concentration using PRISMA software.
Tissue collection
After euthanasia, the following fragments of intestinal tissue will be collected for histological analysis by immunofluorescence and gene expression analysis by molecular biology:
-Interposition Group: median segment of transposed ileum and segment adjacent to ileal anastomosis (ileum remaining in normal position) ( Figure 7A ).
-Control Group: ileum segment and jejunum segment ( Figure 7B ). 
Histological analysis by immunofluorescence
One-centimetre tissue samples for histological analysis by immunofluorescence will be cryopreserved in increasing sucrose concentrations (10% and 20% for 4 hours at 4°C and 30%
for 12 hours at 4°C), frozen in liquid nitrogen, and kept at -80°C until analysis. Three-to fivemicron-thick sections will be cut from the tissues using a cryostat (Leica) and mounted on silanated slides (BMF).
To block nonspecific staining, the slides will be incubated in phosphate-buffered saline (PBS) pH 7.4 + 1% bovine serum albumin (BSA) for 30 minutes at room temperature. For binding with primary antibody, the slides will be incubated with specific antibody (anti-GLP-1 and others, Abcam) diluted in 1% PBS/albumin buffer (Sigma A9647) for 1 hour at 37°C or for 16-18 hours at 4°C in a humid chamber. Next, they will be washed three times with 1%
PBS/albumin for 5-10 minutes and incubated with a fluorophore-conjugated secondary antibody (FITC, Rhodamine, or Alexa Fluor 488, Invitrogen) for 90 minutes at 4°C in a humid chamber following the manufacturer's instructions. After incubation, the slides will be washed three times with 1% PBS/albumin for 5-10 minutes and incubated with the second primary antibody, and the incubation and washing steps described above will be repeated. Finally, the slides will be incubated with 4',6-diamidino-2-phenylindole (DAPI, Invitrogen) for 30 minutes at 37°C, mounted on 1% glycerol-coated microscopy slides, and stored refrigerated and protected from light until analysis.
Immunoexpression of GLP-1, an L-cell marker, and other relevant genes will be assessed under a fluorescence microscope using appropriate filters for each fluorochrome. To isolate total RNA, we will homogenise each sample using QIAzol reagent (QIAzol Lysis Reagent, Qiagen) on a Polytron tissue processor. After precipitation with ethanol, total RNA will be isolated using a commercial kit (RNeasy Mini Kit, Qiagen), and genomic DNA will be eliminated (RNase Free-DNase Set, Qiagen). Total RNA concentration and purity will be assessed by spectrophotometry and agarose gel electrophoresis.
Synthesis of cDNA and fluorescence
To convert total RNA into DNA, cDNA will be synthesised using a cDNA synthesis kit (RT 2 Easy First Strand Kit, Qiagen). Next, we will add reagents from the RT 2 SYBR Green Master
Mix kit (Qiagen) to the synthesised cDNA for fluorescent intercalator emission to allow detection and analysis of the relative expression of genes of interest.
Real-time PCR
Samples will be subjected to real-time polymerase chain reaction (real-time PCR) using an ABI 7500 thermocycler (Applied Biosystems, USA) with 5 specific kits, one per analysed pathway (Stem Cells, Notch, Diabetes, Stem Cell Signalling, and Wnt) and a kit specially customised for this study (Enteroendocrine Differentiation). The complete list of genes to be analysed with each kit is described in the tables below. Apoptosis Genes: Gsk3b, Notch1, Notch2, Psen1. Cell Cycle Regulators: Ccne1, Cdc16, Figf (Vegfd), Gsk3b, Jag2, Notch2, Pcaf (Kat2b). Cell Growth and Migration: Jag2, Lrp5, Notch2, Psen1, Shh, Wisp1. Cell Proliferation: Ctnnb1, Figf, Gsk3b, Jag1, Jag2, Notch2, Numb, Pcaf (Kat2b), Shh. Genes Regulating Cell Differentiation: Ctnnb1, Dll1, Gsk3b, Jag1, Jag2, Notch1, Notch2, Notch3, Notch4, Runx1 (Aml1), Shh. Neurogenesis: Dll1, Heyl, Jag1, Notch2, Numb, Pofut1, Rfng, Zic2 (Hpe5). Regulation of Transcription: Aes (Grg5), Ctnnb1, Ep300, Gli1, Hdac1, Heyl, Hoxb4, Hr, Mycl1 (Lmyc1), Ncor2, Notch1, Notch2, Notch3, Notch4, Pcaf (Kat2b), Rbpjl, Runx1 (Aml1), Tead1, Tle1.
Other Genes with Unspecified Functions: Adam17 (Cd156b), Cbl, Gbp2, Il6st (Gp130), Lfng, Lmo2, Map1b, Mfng, Mmp7 (Matrilysin), Neurl (Neu1), Sel1l, Supt6h. The number of initial template strands can be calculated from the Ct. The equation
Ns=No(1+E) n describes exponential PCR amplification, where "Ns" in the number of template strands at a given reaction cycle, "No" is the number of initial template strands, "E" is efficiency of the amplification reaction, and "n" is the number of cycles. Assuming that reaction efficiency is 100% (log E=1) and "n" is a selected amplification point identical for all samples, we can calculate the number of initial template strands using the following equation: This method will be used in our study to calculate the relative expression levels of genes of interest. The relative expression levels of genes of interest will be compared among the different segments from different groups of animals (IG ileum, SG ileum, CG jejunum, and ileum).
Statistical analysis
The variables will be summarised for each study group using the pertinent descriptive statistics: absolute (n) and relative (%) frequency, or mean, standard deviation (s.d.), median, maximum, and minimum values. The data will be analysed using parametric or non-parametric tests according to the observed distribution.
For normally distributed data, analysis of variance will be applied with two fixed factors: groups (4 levels: IG, SG, CG1, and CG2) and assessment time-point (3 levels: Week 12 (W12), Week 20 (W20), and Week 28 (W28)). For the variables assessed weekly, the test will have 16 levels corresponding to each week. For non-normally distributed data, the MannWhitney test will be applied to compare techniques within each assessment, and the Friedman test will be applied to related samples to compare variations within each technique. The presence of an association between qualitative variables will be assessed by the chi-squared test or Fisher's exact test. The level of significance will be set to 0.05 (α = 5%), and p values lower than this value will be considered significant.
